Espero BioPharma named as fastest-growing private company in Northeast Florida

JACKSONVILLE, Fla, July 26, 2017 –The Jacksonville Business Journal has named Espero BioPharma as the fastest-growing private company in Northeast Florida. The ranking is based on the company’s average annual revenue growth over the past three years. Logistics, finance, health care, technology, law and more — all of the major industries in the Greater Jacksonville area are represented on this …

Espero Pharmaceuticals and Armetheon to Merge and Create a 
Premier Cardiovascular Focused Biopharmaceutical Company

JACKSONVILLE, Fla. and MENLO PARK, Calif. (March 30, 2017) – Espero Pharmaceuticals, Inc., a privately held, commercial-stage cardiovascular pharmaceutical company, and Armetheon, Inc., a privately held, late-clinical stage pharmaceutical company developing innovative novel drugs addressing major unmet needs in cardiovascular diseases, today announced their plans to merge. Upon completion of the merger, which is expected to occur in the second …

Armetheon Announces European Medicines Agency’s Support for 1000 Patient Single Phase 3 Study prior to MAA Filing for its Novel Oral Anticoagulant Tecarfarin

MENIO PARK, Calif., Feb. 14, 2017 /PRNewswire/ – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced it has received advice from the European Medicines Agency (EMA) Scientific Advice Working Group (SAWG) for the development of its novel oral anticoagulant tecarfarin. The SAWG advised that Armetheon can conduct a single1000 patient pivotal study prior …

Armetheon announces issuance of a new U.S. patent for its Phase 2 clinical stage novel oral antiarrhythmic budiodarone

MENIO PARK, Calif., Feb. 13, 2017 – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced the issuance on January 24, 2017 by the U.S. Patent and Trademark Office (USPTO) of a new patent covering the company’s novel oral antiarrhythmic, budiodarone, the only known novel anti-arrhythmic in clinical development. The new U.S. Patent No. …

Armetheon Reaches Agreement with FDA to Conduct a 1000 Patient Single Phase 3 Study Prior to NDA Filing for its Novel Oral Anticoagulant Tecarfarin

MENIO PARK, Calif., Feb. 9, 2017 /PRNewswire/ – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced it has reached agreement with the U.S. Food and Drug Administration (FDA) for a single 1000 patient final pivotal trial for its drug candidate, tecarfarin (Tecarfarin for AntiCoagulation Trial or TACT) prior to filing an NDA, which …

Espero Acquires DURLAZA® (aspirin) Extended Release Capsules 
for Secondary Prevention of Stroke and Acute Cardiac Events

JACKSONVILLE, Fla. (February 7, 2017) – Espero Pharmaceuticals, Inc., a commercial-stage cardiovascular pharmaceutical company, today announced that the company has acquired the global rights to DURLAZA® (aspirin) Extended Release Capsules.Company officials will provide an update on February 13, 2017 at the BIO CEO & Investor Conference held at the Waldorf Astoria New York. DURLAZA is an FDA-approved and commercially available …

GONITRO™ to Participate in First-of-its-Kind 
Comparative Effectiveness ISCHEMIA Clinical Trial Sponsored by the National Institutes of Health

JACKSONVILLE, Fla. (Jan. 19, 2017) – Espero Pharmaceuticals, Inc., a commercial-stage cardiovascular pharmaceutical company, will donate GONITRO™ (nitroglycerin sublingual powder) to the ongoing International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) clinical trial and to the ISCHEMIA-Chronic Kidney Disease (CKD) ancillary trial. The company’s executives provided an update during last week’s annual JP Morgan Healthcare Conference …

Espero Pharmaceuticals CEO, Quang Pham, is Honored by BioFlorida with its Entrepreneur of the Year Award

The Entrepreneur of the Year Award recognizes an entrepreneur who has made extraordinary contributions to the growth of life sciences in the leadership of a company or institution. The 2016 Entrepreneur of the Year Award was presented to Quang Pham, Founder and CEO of Espero Pharmaceuticals, a privately held, cardiovascular pharmaceutical company focused on compounds with proven safety and efficacy …

Espero Pharmaceuticals Announces the Availability of FDA-Approved GONITRO™ (Nitroglycerin) Sublingual Powder in the U.S.

New Short-Acting Nitrate Powder Now Available in Single Dose Packets 
for Acute Relief of an Angina Pectoris Attack JACKSONVILLE, Fla. (Sept. 27, 2016) – Espero Pharmaceuticals Inc., a privately held specialty pharmaceutical company, today announced the commercial availability of GONITRO™ (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. GONITRO™ …

Armetheon Announces Positive Results of Pharmacokinetics Study of Tecarfarin versus Warfarin

Clinical data show promise of tecarfarin in chronic kidney disease patients requiring anticoagulation MILPITAS, Calif., Aug. 25, 2016 /PRNewswire/ – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced results from its Phase 1 clinical trial evaluating the effect of severe chronic kidney disease on the pharmacokinetics (PK) of tecarfarin, Armetheon’s lead candidate, and …